Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reckitt’s Revenues Soar On Strength Of Adams Brands, Product Innovations

This article was originally published in The Tan Sheet

Executive Summary

Reckitt-Benckiser's revenues soared 13 percent in fiscal 2008 as health care and personal product sales grew more than twice as fast as its other segments - a trend the firm expects to continue despite private label competition and the global economic slump
Advertisement

Related Content

NACDS New Products In Brief
NACDS New Products In Brief
NACDS New Products In Brief
Amid Growth, Reckitt To Launch Mucinex In Emerging Markets Ahead of EU
Amid Growth, Reckitt To Launch Mucinex In Emerging Markets Ahead of EU
Reckitt Sees End Of Mucinex Exclusivity Despite Delay Attempts
Watson Files ANDA For Mucinex DM, Gets In Line For Generic Guaifenesin
Adams’ Brands Front And Center In Reckitt’s Present, Future
Reckitt Benckiser closer to acquiring Adams
Adams Faces Another Mucinex Challenge, Prepares For Product Launches

Topics

Advertisement
UsernamePublicRestriction

Register

PS102619

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel